Ocumension Therapeutics (1477.HK)

HKD 5.55

(0.36%)

EBITDA Summary of Ocumension Therapeutics

Ocumension Therapeutics's latest annual EBITDA in 2023 was -320.61 Million CNY , up 9.02% from previous year.
Ocumension Therapeutics's latest quarterly EBITDA in 2023 FY was N/A , up 9.02% from previous quarter.
Ocumension Therapeutics reported an annual EBITDA of -359.97 Million CNY in 2022, up 3.91% from previous year.
Ocumension Therapeutics reported an annual EBITDA of -371.3 Million CNY in 2021, up 83.63% from previous year.
Ocumension Therapeutics reported a quarterly EBITDA of -77.15 Million CNY for 2023 Q4, down 0.0% from previous quarter.
Ocumension Therapeutics reported a quarterly EBITDA of N/A for 2023 FY, up 9.02% from previous quarter.

Annual EBITDA Chart of Ocumension Therapeutics (2023 - 2018)

Historical Annual EBITDA of Ocumension Therapeutics (2023 - 2018)

Year	EBITDA	EBITDA Growth
2023	-320.61 Million CNY	9.02%
2022	-359.97 Million CNY	3.91%
2021	-371.3 Million CNY	83.63%
2020	-2.26 Billion CNY	-69.87%
2019	-1.32 Billion CNY	-537.42%
2018	-59.31 Million CNY	0.0%

Year	EBITDA	EBITDA Growth
2023 Q2	-100.72 Million CNY	0.0%
2023 Q4	-77.15 Million CNY	0.0%
2023 FY	- CNY	9.02%
2023 Q1	-100.72 Million CNY	9.09%
2023 Q3	-77.15 Million CNY	23.39%
2022 Q1	-103.58 Million CNY	-4.26%
2022 Q2	-103.58 Million CNY	0.0%
2022 Q4	-110.79 Million CNY	0.0%
2022 Q3	-110.79 Million CNY	-6.95%
2022 FY	- CNY	3.91%
2021 Q1	-88.8 Million CNY	23.63%
2021 FY	- CNY	83.63%
2021 Q4	-99.35 Million CNY	0.0%
2021 Q3	-99.35 Million CNY	-11.88%
2021 Q2	-88.8 Million CNY	0.0%
2020 Q3	-116.28 Million CNY	-7.64%
2020 Q2	-108.02 Million CNY	0.0%
2020 FY	- CNY	-69.87%
2020 Q1	-108.02 Million CNY	-114.23%
2020 Q4	-116.28 Million CNY	0.0%
2019 Q3	-50.42 Million CNY	-74.33%
2019 FY	- CNY	-537.42%
2019 Q4	-50.42 Million CNY	0.0%
2019 Q1	-28.92 Million CNY	0.0%
2019 Q2	-28.92 Million CNY	0.0%
2018 FY	- CNY	0.0%

Peer EBITDA Comparison of Ocumension Therapeutics

Name	EBITDA	EBITDA Difference
Uni-Bio Science Group Limited	91.23 Million HKD	451.425%
CK Life Sciences Int'l., (Holdings) Inc.	486.79 Million HKD	165.863%